{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:16:55Z","timestamp":1791303415647,"version":"4.1.0"},"reference-count":44,"publisher":"American Medical Association (AMA)","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Social determinants of health (SDOH) influence health outcomes, including those of sickle cell disease (SCD), despite advancements in treatments like disease-modifying therapies.<\/jats:p><\/jats:sec>Objective<\/jats:title>To investigate the association of SDOH with SCD mortality rates from 2016 to 2020.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>This cross-sectional study combined county-level data from the Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry Social Vulnerability Index (SVI) with SCD mortality data from the Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database from January 1, 2016, to December 31, 2020. US counties were divided into 4 quartile (Q) models according to their SVI scores. Deaths from SCD in the US among patients of all ages were included. Data analysis occurred from March to April 2024.<\/jats:p><\/jats:sec>Exposure<\/jats:title>SVI score.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Age-adjusted mortality rates (AAMRs) per 1\u202f000\u202f000 individuals were measured. Rate ratios (RRs) were obtained by comparing county-specific AAMRs of SVI-Q4 with SVI-Q1.<\/jats:p><\/jats:sec>Results<\/jats:title>From 2016 to 2020, among a total population of 1\u202f633\u202f737\u202f771 individuals, there were 2635 deaths from SCD (1289 male [49.1%] and 1336 female [50.9%]). There were 1480 deaths in Q4, 687 deaths in Q3, 344 deaths in Q2, and 114 deaths in Q1. Higher SVI was associated with 2.11 excess deaths per 1\u202f000\u202f000 individuals (RR, 4.90; 95% CI, 4.81-5.00). Similar trends were seen for both males (RR, 4.56; 95% CI, 4.44-4.69) and females (RR, 5.85; 95% CI, 5.68-6.03). Middle-aged patients with SCD had the highest mortality rate in Q4, with 3.45 excess deaths per 1\u202f000\u202f000 individuals (RR, 4.97; 95% CI, 4.85-5.09). Higher SVI was associated with 2.29 excess deaths per 1\u202f000\u202f000 individuals in African American individuals with SCD (RR, 1.24; 95% CI, 1.22-1.27]). In White individuals with SCD, higher SVI was associated with 0.12 excess deaths per 1\u202f000\u202f000 individuals (RR not available due to unreliable data in Q1). When stratifying by census region, the highest level of SCD-related mortality was in the Northeast, with higher SVI associated with 3.16 excess deaths per 1\u202f000\u202f000 individuals (RR, 8.02; 95% CI, 7.66-8.40).<\/jats:p><\/jats:sec>Conclusions<\/jats:title>In this cross-sectional study of the association of SVI with SCD mortality rates, higher SVI was associated with higher SCD mortality across US counties. These findings underscore the importance of addressing social determinants of health to improve mortality outcomes among patients with SCD.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2024.40599","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T15:32:27Z","timestamp":1727710347000},"page":"e2440599","source":"Crossref","is-referenced-by-count":15,"title":["Social Vulnerability and Sickle Cell Disease Mortality in the US"],"prefix":"10.1001","volume":"7","author":[{"given":"Jia Yi","family":"Tan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, New York Medical College at St Michael\u2019s Medical Center, Newark, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Jian","family":"San","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-Hao","family":"Yeo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Pediatrics, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kok Hoe","family":"Chan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth Houston)"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid S.","family":"Shaaban","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Internal Medicine, New York Medical College at St Michael\u2019s Medical Center, Newark, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Ezekwudo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Oakland University William Beaumont School of Medicine, Royal Oak, Michigan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modupe","family":"Idowu","sequence":"additional","affiliation":[{"name":"Division of Hematology, Department of Internal Medicine, McGovern Medical School at the University of Texas Health Science Center at Houston (UTHealth Houston)"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,9,30]]},"reference":[{"issue":"8","key":"zoi241176r1","doi-asserted-by":"publisher","first-page":"e585","DOI":"10.1016\/S2352-3026(23)00118-7","article-title":"Global, regional, and national prevalence and mortality burden of sickle cell disease, 2000-2021: a systematic analysis from the global burden of disease study 2021.","volume":"10","author":"Collaborators","year":"2023","journal-title":"Lancet Haematol"},{"key":"zoi241176r2","doi-asserted-by":"publisher","first-page":"18010","DOI":"10.1038\/nrdp.2018.10","article-title":"Sickle cell disease.","volume":"4","author":"Kato","year":"2018","journal-title":"Nat Rev Dis Primers"},{"issue":"3S","key":"zoi241176r5","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.annemergmed.2020.08.009","article-title":"Trends in sickle cell disease-related mortality in the United States, 1979 to 2017.","volume":"76","author":"Payne","year":"2020","journal-title":"Ann Emerg Med"},{"issue":"9105","key":"zoi241176r6","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0140-6736(05)78941-8","article-title":"FDA approves first drug for sickle-cell anaemia.","volume":"351","author":"Ault","year":"1998","journal-title":"Lancet"},{"issue":"13","key":"zoi241176r7","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"issue":"3","key":"zoi241176r8","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.4584","article-title":"Changes in hydroxyurea use among youths enrolled in Medicaid with sickle cell anemia after 2014 revision of clinical guidelines.","volume":"6","author":"Reeves","year":"2023","journal-title":"JAMA Netw Open"},{"key":"zoi241176r9","doi-asserted-by":"publisher","DOI":"10.1177\/2333794X19847026","article-title":"Barriers to Pediatric Sickle Cell Disease Guideline Recommendations.","volume":"6","author":"Cabana","year":"2019","journal-title":"Glob Pediatr Health"},{"issue":"18","key":"zoi241176r10","doi-asserted-by":"publisher","first-page":"4463","DOI":"10.1182\/bloodadvances.2020001701","article-title":"Intentional and unintentional nonadherence to hydroxyurea among people with sickle cell disease: a qualitative study.","volume":"4","author":"Hodges","year":"2020","journal-title":"Blood Adv"},{"key":"zoi241176r11","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.921432","article-title":"Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: report from a U.S. regional collaborative.","volume":"13","author":"Treadwell","year":"2022","journal-title":"Front Genet"},{"issue":"1","key":"zoi241176r12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1001\/jama.2022.10233","article-title":"Sickle cell disease: a review.","volume":"328","author":"Kavanagh","year":"2022","journal-title":"JAMA"},{"issue":"1","key":"zoi241176r13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s40265-019-01254-2","article-title":"Crizanlizumab: first approval.","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"issue":"5","key":"zoi241176r14","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease.","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"zoi241176r15","doi-asserted-by":"publisher","first-page":"2659","DOI":"10.1007\/s00277-023-05388-y","article-title":"Recent national trends in outcomes and economic disparities among adult sickle cell disease-related admissions.","volume":"102","author":"Deenadayalan","year":"2023","journal-title":"Ann Hematol"},{"issue":"1","key":"zoi241176r16","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1186\/s12913-024-10717-6","article-title":"Social determinants of health and treatment center affiliation: analysis from the sickle cell disease implementation consortium registry.","volume":"24","author":"Mendez","year":"2024","journal-title":"BMC Health Serv Res"},{"issue":"21","key":"zoi241176r17","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.029649","article-title":"Impact of social vulnerability on diabetes-related cardiovascular mortality in the United States.","volume":"12","author":"Bashar","year":"2023","journal-title":"J Am Heart Assoc"},{"issue":"16","key":"zoi241176r18","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1161\/CIRCULATIONAHA.121.054516","article-title":"social vulnerability and premature cardiovascular mortality among US counties, 2014 to 2018.","volume":"144","author":"Khan","year":"2021","journal-title":"Circulation"},{"issue":"1","key":"zoi241176r19","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1513\/AnnalsATS.202202-136OC","article-title":"Association of county-degree social vulnerability with chronic respiratory disease mortality in the United States.","volume":"20","author":"Lee","year":"2023","journal-title":"Ann Am Thorac Soc"},{"issue":"12","key":"zoi241176r21","doi-asserted-by":"publisher","first-page":"2078","DOI":"10.1007\/s00125-022-05785-4","article-title":"Urban-rural disparities in diabetes-related mortality in the USA 1999-2019.","volume":"65","author":"Kobo","year":"2022","journal-title":"Diabetologia"},{"issue":"6","key":"zoi241176r23","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1177\/0033354919881438","article-title":"Reducing health care disparities in sickle cell disease: a review.","volume":"134","author":"Lee","year":"2019","journal-title":"Public Health Rep"},{"issue":"2","key":"zoi241176r24","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1353\/hpu.2018.0060","article-title":"Social and behavioral factors in sickle cell disease: employment predicts decreased health care utilization.","volume":"29","author":"Williams","year":"2018","journal-title":"J Health Care Poor Underserved"},{"issue":"4","key":"zoi241176r25","doi-asserted-by":"publisher","first-page":"626","DOI":"10.3324\/haematol.2016.153791","article-title":"Risk factors for mortality in adult patients with sickle cell disease: a meta-analysis of studies in North America and Europe.","volume":"102","author":"Maitra","year":"2017","journal-title":"Haematologica"},{"key":"zoi241176r26","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.socscimed.2017.01.010","article-title":"The threat of home eviction and its effects on health through the equity lens: a systematic review.","volume":"175","author":"V\u00e1squez-Vera","year":"2017","journal-title":"Soc Sci Med"},{"issue":"7","key":"zoi241176r27","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/medicina55070385","article-title":"Impact of depression in sickle cell disease hospitalization-related outcomes: an analysis of the national inpatient sample (NIS).","volume":"55","author":"Onyeaka","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"zoi241176r28","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/HRP.0000000000000162","article-title":"Depression and anxiety in heart failure: a review.","volume":"26","author":"Celano","year":"2018","journal-title":"Harv Rev Psychiatry"},{"issue":"1","key":"zoi241176r29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.31887\/DCNS.2018.20.1\/nsartorius","article-title":"Depression and diabetes.","volume":"20","author":"Sartorius","year":"2018","journal-title":"Dialogues Clin Neurosci"},{"issue":"7","key":"zoi241176r30","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/0333102416638520","article-title":"Genetic epidemiology of migraine and depression.","volume":"36","author":"Yang","year":"2016","journal-title":"Cephalalgia"},{"issue":"16","key":"zoi241176r31","doi-asserted-by":"publisher","first-page":"3804","DOI":"10.1182\/bloodadvances.2020001743","article-title":"Building access to care in adult sickle cell disease: defining models of care, essential components, and economic aspects.","volume":"4","author":"Kanter","year":"2020","journal-title":"Blood Adv"},{"issue":"6","key":"zoi241176r32","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1016\/j.hoc.2022.07.013","article-title":"Economics of sickle cell disease and evidence to support comprehensive care.","volume":"36","author":"Nero","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"issue":"1","key":"zoi241176r33","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1182\/hematology.2019000053","article-title":"Sickle cell disease: a comprehensive program of care from birth.","volume":"2019","author":"de Montalembert","year":"2019","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"3","key":"zoi241176r34","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/ajh.10305","article-title":"Frequent and prolonged hospitalizations: a risk factor for early mortality in sickle cell disease patients.","volume":"72","author":"Houston-Yu","year":"2003","journal-title":"Am J Hematol"},{"issue":"2","key":"zoi241176r35","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/bjh.14655","article-title":"Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence, and impact on mortality.","volume":"178","author":"Brunson","year":"2017","journal-title":"Br J Haematol"},{"issue":"3","key":"zoi241176r36","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1161\/CIRCULATIONAHA.122.059174","article-title":"Racial and ethnic differences in all-cause and cardiovascular disease mortality: the MESA study.","volume":"146","author":"Post","year":"2022","journal-title":"Circulation"},{"issue":"16","key":"zoi241176r37","doi-asserted-by":"publisher","first-page":"431","DOI":"10.15585\/mmwr.mm7216a4","article-title":"Stroke mortality among Black and White adults aged =35 years before and during the COVID-19 pandemic - United States, 2015-2021.","volume":"72","author":"Yang","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"177","key":"zoi241176r38","first-page":"1","article-title":"Demographic variation in health insurance coverage: United States, 2021.","author":"Cha","year":"2022","journal-title":"Natl Health Stat Report"},{"issue":"1","key":"zoi241176r39","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.amepre.2021.02.014","article-title":"Health insurance disruptions and care access and affordability in the U.S.","volume":"61","author":"Yabroff","year":"2021","journal-title":"Am J Prev Med"},{"issue":"6","key":"zoi241176r40","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1016\/j.hoc.2022.08.008","article-title":"Structural racism and impact on sickle cell disease: sickle cell lives matter.","volume":"36","author":"Smith","year":"2022","journal-title":"Hematol Oncol Clin North Am"},{"issue":"2","key":"zoi241176r41","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1177\/003335491312800206","article-title":"Mortality rates and age at death from sickle cell disease: U.S., 1979-2005.","volume":"128","author":"Lanzkron","year":"2013","journal-title":"Public Health Rep"},{"issue":"12","key":"zoi241176r42","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1542\/hpeds.2021-005806","article-title":"Hospital use and mortality in transition-aged patients with sickle cell disease.","volume":"11","author":"Fasipe","year":"2021","journal-title":"Hosp Pediatr"},{"issue":"10","key":"zoi241176r43","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1002\/ajh.22106","article-title":"When children with sickle-cell disease become adults: lack of outpatient care leads to increased use of the emergency department.","volume":"86","author":"Hemker","year":"2011","journal-title":"Am J Hematol"},{"key":"zoi241176r44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcrp.2023.200224","article-title":"Alcoholic cardiomyopathy mortality and social vulnerability index: a nationwide cross-sectional analysis.","volume":"19","author":"Shahid","year":"2023","journal-title":"Int J Cardiol Cardiovasc Risk Prev"},{"key":"zoi241176r3","unstructured":"American Society of Hematology. Sickle cell disease. Accessed March 21, 2024. https:\/\/www.hematology.org\/education\/patients\/anemia\/sickle-cell-disease"},{"key":"zoi241176r4","unstructured":"US Centers for Disease Control and Prevention. Data and statistics on sickle cell disease. Updated May 15, 2024. Accessed September 3, 2024. https:\/\/www.cdc.gov\/sickle-cell\/data\/"},{"key":"zoi241176r20","unstructured":"US Centers for Disease Control and Prevention. About multiple cause of death, 1999-2020. CDC Wonder. Accessed March 7, 2024. https:\/\/wonder.cdc.gov\/controller\/datarequest\/D77;jsessionid=DCB68A81611D9EE2707CBBAFF327."},{"key":"zoi241176r22","unstructured":"US Department of Health and Human Service, National Center for Health Statistics. 2013 NCHS urban-rural classification scheme for counties: vital and health statistics Series 2 No. 166. 2014. Accessed August 19, 2024. https:\/\/www.cdc.gov\/nchs\/data\/series\/sr_02\/sr02_166.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2824207\/tan_2024_oi_241176_1727207864.28248.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T15:32:30Z","timestamp":1727710350000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2824207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,30]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.40599","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,30]]}}}